TrialJournal of clinical pharmacology2022

Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.

Cody J Peer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.